A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

Exclusion Criteria

• •Co-existing Condition:
• •Patients with any of the following symptoms of conditions are excluded:
• •Active extraocular CMV disease.
• •Severe uncontrolled diarrhea or evidence of malabsorption.
• •Concurrent Medication:
• •Excluded:
• •Foscarnet.
• •Cidofovir.
• •CMV hyperimmune globulin.
• •Probenecid.
• •Patients with the following prior conditions are excluded:
• •Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic retinal assessment.
• •Simultaneous participation in another study (unless approved by Roche).
• •Required:
• •A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir.
• •Approval required for prior use of investigational anti-CMV agents.